在血管质量倡议数据库中验证WIfI分类
本研究基于血管质量倡议外周血管介入数据库2013至2024年数据,对28,727例有长期随访的慢性肢体威胁性缺血患者验证WIfI分类,发现WIfI分期越高,大截肢或死亡风险越高,且WIfI临床分期与终末期肾病均为独立相关因素。
要点
- WIfI分期越高,1年大截肢或死亡率显著增加(1期7.7%至4期20.2%,P < .001)。
- 校正后WIfI分期2、3、4期相较于1期的大截肢或死亡风险分别为HR 1.17、1.41、1.69。
- 终末期肾病亦为独立风险因素(HR 1.96),支持将WIfI评分整合入外周动脉疾病相关模块。
核心结论
- 本研究在VQI PVI数据库中验证了WIfI分类,证实其预测CLTI患者大截肢和死亡的价值。
- 较高的WIfI分期与大截肢和死亡风险增加独立相关,凸显了将WIfI评分纳入所有外周动脉疾病相关VQI模块的重要性。
研究设计与样本
- 回顾性分析VQI PVI数据库2013至2024年数据,纳入可推导WIfI评分的CLTI患者,最终28,727例有长期随访者纳入分析。
主要发现
- 共280,706例接受PVI,其中130,575例为CLTI,33%(n = 42,858)可推导WIfI分期,28,727例有长期随访并纳入研究。
- 3271例(11.4%)在LER后接受大截肢,截肢组更年轻且男性、西班牙裔或非裔美国人比例更高,多数危险因素比例更高且WIfI分期更高。
- Kaplan-Meier分析显示1年大截肢或死亡率随WIfI分期递增:1期7.7%、2期8.2%、3期14.7%、4期20.2%(P < .001)。
- Cox回归显示WIfI临床分期与终末期肾病独立关联大截肢或死亡:2期vs 1期HR 1.17(95%CI 1.06-1.27),3期vs 1期HR 1.41(95%CI 1.31-1.54),4期vs 1期HR 1.69(95%CI 1.54-1.82),终末期肾病HR 1.96(95%CI 1.8-2.14)。
关键数值与推荐
- WIfI分期与1年大截肢或死亡率:1期7.7%、2期8.2%、3期14.7%、4期20.2%(P < .001)。
- 大截肢或死亡的独立风险比:2期vs 1期HR 1.17(95%CI 1.06-1.27),3期vs 1期HR 1.41(95%CI 1.31-1.54),4期vs 1期HR 1.69(95%CI 1.54-1.82)。
- 终末期肾病与大截肢或死亡独立相关:HR 1.96(95%CI 1.8-2.14)。
临床怎么用
- 作者认为应捕获WIfI评分并将其整合入所有与外周动脉疾病治疗相关的VQI模块。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification was introduced in 2014 and has been validated in multiple institutional series as a useful tool to assess the severity of chronic limb-threatening ischemia (CLTI) and predict the risk of major amputation after lower extremity revascularization (LER). The Vascular Quality Initiative (VQI) Peripheral Vascular Interventions (PVI) database captures data on wounds, ischemia, and infection, which are key components of the WIfI score, but does not provide the complete WIfI stage. The aim of this study is to validate the WIfI classification in the VQI PVI database and analyze the different combinations of components. METHODS: The VQI PVI data files (2013-2024) were reviewed for patients with CLTI with available data from which to derive WIfI scores. The characteristics of patients who underwent major amputation during follow-up were compared with those who did not. Kaplan-Meier curves were compared for major amputation, reintervention, and mortality for the various WIfI stages. Cox regression analysis was performed to assess for independent risk factors associated with major amputation. RESULTS: A total of 280,706 individuals underwent PVI procedures, and 130,575 presented with CLTI. WIfI stage derivation was possible for 33% (n = 42,858) of patients, 28,727 of whom had long-term follow up and were included in this study. A total of 3271 patients (11.4%) underwent major amputation after LER. Patients requiring amputation were significantly younger and more likely to be male, Hispanic, or African American compared with patients who did not undergo amputation. Patients in the amputation group were more likely to be affected by most risk factors and presented with higher WIfI stages. On Kaplan-Meier analysis, the estimates of 1-year major amputation or mortality significantly increased with each WIfI stage (stage 1, 7.7%; stage 2, 8.2%; stage 3, 14.7%; stage 4, 20.2%; P < .001). Cox regression analyses demonstrated that WIfI clinical stage (stage 2 vs 1, hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.06-1.27; stage 3 vs 1, HR, 1.41; 95% CI, 1.31-1.54; stage 4 vs 1, HR, 1.69; 95% CI, 1.54-1.82) and end-stage renal disease (HR, 1.96; 95% CI, 1.8-2.14) were independently associated with major amputation or mortality. CONCLUSIONS: In conclusion, this study validated the WIfI classification in the VQI PVI database, confirming its value in predicting major amputation and mortality in patients with CLTI. Higher WIfI stages were independently associated with increased risk of major amputation and mortality, highlighting the importance of capturing and integrating the WIfI score into all VQI modules related to treatment of peripheral artery disease.
引用
- Alameddine D, Satam K, Slade MD, et al. Validation of the WIfI classification in the Vascular Quality Initiative database. J Vasc Surg. 2025. PMID: 40056961. doi:10.1016/j.jvs.2025.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。